Detection and verification of coexisting diagnostic markers in plasma and serum of patients with non-small-cell lung cancer

To screen and identify the potential biomarkers co-existing in plasma and serum of patients with non-small-cell lung cancer (NSCLC), and establish appropriate diagnostic models. A cohort of 195 plasma samples and 180 serum samples were obtained from healthy controls (HCs), adenocarcinoma (AdC) and s...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Future oncology (London, England) England), 2021-11, Vol.17 (32), p.4355-4369
Hauptverfasser: Yu, Mengjie, Sun, Runbin, Zhao, Yuqing, Shao, Feng, Zhu, Wei, Aa, Jiye
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:To screen and identify the potential biomarkers co-existing in plasma and serum of patients with non-small-cell lung cancer (NSCLC), and establish appropriate diagnostic models. A cohort of 195 plasma samples and 180 serum samples were obtained from healthy controls (HCs), adenocarcinoma (AdC) and squamous cell carcinoma (SqCC) patients enrolled from the First Affiliated Hospital of Nanjing Medical University. Metabolites in plasma and serum were analyzed by GC-MS. Hypoxanthine was found to have good performance in the differential diagnosis of NSCLC (including AdC and SqCC) and HC (area under the receiver operating characteristic [AUROC] ≥0.85). Combinations of metabolites could be used for differential diagnosis of NSCLC and HC (AUROC >0.93), AdC and HC (AUROC >0.91), SqCC and HC (AUROC >0.95), AdC and SqCC (AUROC >0.72). Metabolomics based on GC-MS can screen and identify the differential metabolites coexisting in plasma and serum of patients with NSCLC, and prediction models established by this method can be used for the differential diagnosis of patients with NSCLC. Non-small-cell lung cancer (NSCLC) is not easy to diagnose. This study was intended to determine metabolites to differentiate NSCLC and healthy control samples (HC). In this study, we collected plasma and serum of NSCLC and HC. Then we performed a metabolomic analysis on these blood samples. The results showed that some metabolites were co-existing in plasma and serum of NSCLC. These co-existing metabolites (such as hypoxanthine, glyceric acid and aspartate) could differentiate NSCLC and HC.
ISSN:1479-6694
1744-8301
DOI:10.2217/fon-2021-0025